375 related articles for article (PubMed ID: 26111727)
21. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
[TBL] [Abstract][Full Text] [Related]
22. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.
Poulain S; Boyle EM; Tricot S; Demarquette H; Doye E; Roumier C; Duthilleul P; Preudhomme C; Maurage CA; Morschhauser F
Br J Haematol; 2015 Jul; 170(2):285-7. PubMed ID: 25643939
[No Abstract] [Full Text] [Related]
23. Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.
Mareschal S; Pham-Ledard A; Viailly PJ; Dubois S; Bertrand P; Maingonnat C; Fontanilles M; Bohers E; Ruminy P; Tournier I; Courville P; Lenormand B; Duval AB; Andrieu E; Verneuil L; Vergier B; Tilly H; Joly P; Frebourg T; Beylot-Barry M; Merlio JP; Jardin F
J Invest Dermatol; 2017 Sep; 137(9):1984-1994. PubMed ID: 28479318
[TBL] [Abstract][Full Text] [Related]
24. The genomic and transcriptional landscape of primary central nervous system lymphoma.
Radke J; Ishaque N; Koll R; Gu Z; Schumann E; Sieverling L; Uhrig S; Hübschmann D; Toprak UH; López C; Hostench XP; Borgoni S; Juraeva D; Pritsch F; Paramasivam N; Balasubramanian GP; Schlesner M; Sahay S; Weniger M; Pehl D; Radbruch H; Osterloh A; Korfel A; Misch M; Onken J; Faust K; Vajkoczy P; Moskopp D; Wang Y; Jödicke A; Trümper L; Anagnostopoulos I; Lenze D; Küppers R; Hummel M; Schmitt CA; Wiestler OD; Wolf S; Unterberg A; Eils R; Herold-Mende C; Brors B; ; Siebert R; Wiemann S; Heppner FL
Nat Commun; 2022 May; 13(1):2558. PubMed ID: 35538064
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
[TBL] [Abstract][Full Text] [Related]
26. Mutational analysis of primary central nervous system lymphoma.
Bruno A; Boisselier B; Labreche K; Marie Y; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Miquel C; Eimer S; Houillier C; Soussain C; Mokhtari K; Daveau R; Hoang-Xuan K
Oncotarget; 2014 Jul; 5(13):5065-75. PubMed ID: 24970810
[TBL] [Abstract][Full Text] [Related]
27. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
28. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
[TBL] [Abstract][Full Text] [Related]
29. Synergistic cooperation and crosstalk between
Wang JQ; Jeelall YS; Humburg P; Batchelor EL; Kaya SM; Yoo HM; Goodnow CC; Horikawa K
J Exp Med; 2017 Sep; 214(9):2759-2776. PubMed ID: 28701369
[No Abstract] [Full Text] [Related]
30. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
[TBL] [Abstract][Full Text] [Related]
31. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
[TBL] [Abstract][Full Text] [Related]
32. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
[TBL] [Abstract][Full Text] [Related]
33. Pathology and new insights in central nervous system lymphomas.
Lebrun L; Allard-Demoustiez S; Salmon I
Curr Opin Oncol; 2023 Sep; 35(5):347-356. PubMed ID: 37439536
[TBL] [Abstract][Full Text] [Related]
34. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
35. An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.
Flümann R; Hansen J; Meinel J; Pfeiffer P; Goldfarb Wittkopf H; Lütz A; Wirtz J; Möllmann M; Zhou T; Tabatabai A; Lohmann T; Jauch M; Beleggia F; Pelzer B; Ullrich F; Höfmann S; Arora A; Persigehl T; Büttner R; von Tresckow B; Klein S; Jachimowicz RD; Reinhardt HC; Knittel G
Blood Adv; 2024 Mar; 8(5):1063-1074. PubMed ID: 38060829
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
[TBL] [Abstract][Full Text] [Related]
37. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
Montesinos-Rongen M; Schmitz R; Brunn A; Gesk S; Richter J; Hong K; Wiestler OD; Siebert R; Küppers R; Deckert M
Acta Neuropathol; 2010 Oct; 120(4):529-35. PubMed ID: 20544211
[TBL] [Abstract][Full Text] [Related]
38. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
39. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
[TBL] [Abstract][Full Text] [Related]
40. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H
Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]